Source: FinanzNachrichten

Cimeio: Cimeio Therapeutics Announces Publication in Nature Demonstrating That CD45 ADC and Shielded HSCs Represent a Potentially Universal Therapy for Blood Cancers

-- Selective and complete eradication of leukemic cells with an ADC targeting the pan-blood marker CD45 -- -- Engineered hematopoietic Stem Cells (HSCs) shielded from the CD45-targeting ADC mainta...

Read full article »
Est. Annual Revenue
$100K-5.0M
Est. Employees
1-25
Thomas Fuchs's photo - CEO of Cimeio

CEO

Thomas Fuchs

CEO Approval Rating

- -/100

Read more